title: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.
abstract: We performed a prospective, randomized, multicenter trial to evaluate the effectiveness of prophylactic inhalations with aerosolized amphotericin B (aeroAmB) to reduce the incidence of invasive aspergillus (IA) infections in patients after chemotherapy or autologous bone marrow transplantation and an expected duration of neutropenia of at least 10 days. From March 1993 until April 1996, 382 patients with leukemias, relapsed high-grade non-Hodgkin lymphomas, or solid tumors were randomized with a 13:10 ratio to receive either prophylactic aeroAmB inhalations at a dose of 10 mg twice daily or no inhalation prophylaxis in an unblinded fashion. The incidence of proven, probable, or possible IA infections was 10 of 227 (4%) in patients who received prophylactic aeroAmB. This did not differ significantly from the 11 of 155 (7%) incidence in patients who received no inhalation prophylaxis (P =.37). Moreover, no differences in the overall mortality (13% v 10%; P =.37) or in the infection-related mortality (8% v 7%; P =.79) were found. In contrast to other nonrandomized trials, we observed no benefit from prophylactic aeroAmB inhalations, but the overall incidence of IA infections was low.
authors.affiliation: Department of Hematology and Oncology, Universitätsklinikum Benjamin Franklin, Berlin, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Schwartz
authors.forename: G
authors.initials: G
authors.lastname: Behre
authors.forename: V
authors.initials: V
authors.lastname: Heinemann
authors.forename: H
authors.initials: H
authors.lastname: Wandt
authors.forename: E
authors.initials: E
authors.lastname: Schilling
authors.forename: M
authors.initials: M
authors.lastname: Arning
authors.forename: A
authors.initials: A
authors.lastname: Trittin
authors.forename: W V
authors.initials: WV
authors.lastname: Kern
authors.forename: O
authors.initials: O
authors.lastname: Boenisch
authors.forename: D
authors.initials: D
authors.lastname: Bosse
authors.forename: K
authors.initials: K
authors.lastname: Lenz
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: W
authors.initials: W
authors.lastname: Siegert
authors.forename: J
authors.initials: J
authors.lastname: Beyer
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001228:Aspergillosis / Q000209:etiology / Q000517:prevention & control*; D001230:Aspergillus; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D011446:Prospective Studies; D012008:Recurrence; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B